Pharma major Lupin Limited (Lupin) has received approval for its Ethacrynic Acid Tablets USP, 25 mg, from the United States Food and Drug Administration (U.S. FDA).
Lupin's Ethacrynic Acid Tablets USP, 25 mg, is the generic version of Edecrin® Tablets, 25 mg, of Bausch Health Americas, Inc. It is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required.
- Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome.
- Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema.
- Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome.
- Intravenous ethacrynic acid sodium is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable.
Ethacrynic Acid Tablets USP (RLD: Edecrin® Tablets) had annual sales of approximately USD 24 million in the US (IQVIA MAT June 2019).
Shares of LUPIN LTD. was last trading in BSE at Rs.772.25 as compared to the previous close of Rs. 765.55. The total number of shares traded during the day was 66398 in over 1735 trades.
The stock hit an intraday high of Rs. 774.85 and intraday low of 757.5. The net turnover during the day was Rs. 51008015.